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Advanced systemic mastocytosis is a rare and still untreatable disease. Blocking antibodies against 
inhibitory receptors, also known as "immune checkpoints", have revolutionized anti-cancer 











cells but also on neoplastic cells. Whether activation of inhibitory receptors through monoclonal 
antibodies can lead to tumor growth inhibition remains mostly unknown. Here we show that the 
inhibitory receptor Siglec-7 is expressed by primary neoplastic mast cells in patients with systemic 
mastocytosis and by mast cell leukemia cell lines. Activation of Siglec-7 by anti-Siglec-7 
monoclonal antibody caused phosphorylation of Src homology region 2 domain-containing 
phosphatase-1 (SHP-1), reduced phosphorylation of KIT and induced growth inhibition in mast 
cell lines. In SCID-beige mice injected with either the human mast cell line HMC-1.1 and HMC-
1.2 or with Siglec-7 transduced B cell lymphoma cells, anti-Siglec-7 monoclonal antibody reduced 
tumor growth by a mechanism involving Siglec-7 cytoplasmic domains in “preventive” and 
“treatment” settings. These data demonstrate that activation of Siglec-7 on mast cell lines can 
inhibit their growth in vitro and in vivo. This might pave the way to additional treatment strategies 
for mastocytosis. 
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Abbreviations 
Anti-Siglec-7 mAb (Anti-S7), Bone Marrow (BM), human mast cell leukemia comprising both HMC-
1.1. and HMC-1.2 (HMC-1 ), indolent systemic mastocytosis (ISM), inhibitory receptor (IR), 
intraperitoneal (ip), Immunoreceptor Tyrosine based Inhibitory Motif (ITIM), mast cells (MCs), mast 
cell leukemia (MCL), monoclonal antibody (mAb), natural killer cells (NK), Src homology 2–
containing inositol polyphosphate 5-phosphatase (SHIP), Src homology region 2 domain-containing 
phosphatase-1 (SHP-1), sialic acid binding Ig-like lectin-7 (Siglec-7), subcutaneous (sc), 
systemic mastocytosis (SM), systemic mastocytosis with an associated hematologic neoplasm 
(SM-AHN), aggressive SM (ASM), SM with an associated hematologic neoplasm (SM-AHN), 













Inhibitory receptors (IRs) are surface receptors that signal primarily after phosphorylation of their 
cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) domains and consequent 
recruitment of the Src homology 2–containing inositol polyphosphate 5-phosphatase (SHIP), Src 
homology region 2 domain-containing phosphatase-1 (SHP-1) or SHP-2 (reviewed in 
Billadeauf(1)). SHP-1 signal transduction pathways lead to modulation of various cellular 
activities including downregulation of immune cell activation(2, 3), induction of cytotoxicity(4), 
cell cycle arrest(5) and apoptosis(6).  
Siglec-7 is an IR belonging to the type-I immunoglobulin superfamily-lectins(7) expressed on 
human but not murine immune cells(8, 9), including mast cells (MCs)(10) and eosinophils(11). 
Once Siglec-7 is activated by its natural ligands (preferably α2, 6-linked disialic gangliosides and 
α2, 8-linked gangliosides) or through specific monoclonal antibodies (mAbs), it inhibits natural 
killer cell (NK) cytotoxicity (12), IgE-dependent MC activation(10) and granulocyte-macrophage 
colony-stimulating factor -induced eosinophil activation(13).  
Siglec-7 is also expressed on neoplastic cells. For example, Siglec-7 expression has been 
previously reported on acute myeloid leukemia cells (AML) belonging to M4 and M5 subtypes 
(14) and its engagement by mAbs has been shown to slightly inhibit in vitro proliferation of chronic 
myeloid leukemia cells (CML) via undefined mechanisms (15).  
Mastocytosis is a rare disease characterized by aberrant growth and accumulation of clonal MCs 
in several different organ systems, including the bone marrow (BM).(16-18) According to the 
World Health Organization classification, mastocytosis is divided into cutaneous mastocytosis, 











neoplasm (SM-AHN), aggressive SM (ASM), mast cell leukemia (MCL) and MC sarcoma (17, 
19, 20).  
In most patients with mastocytosis, neoplastic cells display gain-of-function mutations of the type 
III tyrosine kinase (TK) receptor KIT (21-23) resulting in enhanced survival and autonomous 
growth of MCs (24, 25). The most common KIT mutation found in SM patients is D816V (21, 23, 
26).  Downstream signaling pathways involve several key molecules such as signal transducer and 
activator of transcription 5 (STAT5) (27), phosphoinositide 3-kinase (PI3K)/protein kinase 
B(AKT) (28) and the mechanistic target of rapamycin (mTOR) (29). Several human MCL cell 
lines have been established in the past. The cell lines commonly employed in mastocytosis research 
are HMC-1.1 possessing the G560V KIT mutation, but not the D816V mutation, the HMC-1.2 cell 
line possessing both, the G560V KIT and the D816V KIT mutations (30), the LAD2 cell line (31), 
and the ROSAKIT D816V cell line (32). 
Whereas patients with ISM have an excellent prognosis and therefore do not require intensive 
therapies, patients with advanced SM (ASM, SM-AHN, MCL) have a poor prognosis with short 
survival times (16-18). Therefore, these patients are candidates for interventional anti-neoplastic 
therapies. In young and fit patients with ASM and MCL, polychemotherapy and hematopoietic 
stem cell transplantation can be offered. However, in older co-morbid patients less intensive 
chemotherapy like cladribine, targeted drugs such as Midostaurin or interferon-alpha are usually 
prescribed.(16-18, 33, 34). Although these drugs are quite effective, many of the patients relapse 
after some time or have an upfront resistant disease. For these patients, alternative drugs and new 
experimental agents have to be considered (35, 36).  
In this study, we investigated the expression of Siglec-7 on MCs in mastocytosis patients and asked 












2. Materials and Methods 
2.1 Patient samples 
BM cells were obtained from patients with ISM (n=5), ASM (n=2), SM-AHN (n=2) or MCL (n=1) 
during routine investigations. The two patients with SM-AHN were suffering from ASM with an 
associated myelodysplastic/myeloproliferative overlap neoplasm (ASM-MDS/MPN; n=1) and 
ASM with associated acute myeloid leukemia (ASM-AML; n=1). BM cells were stored frozen in 
liquid nitrogen in a biobank before used. Control BM samples were obtained from two patients 
with multiple myeloma (MM) and one with a Non-Hodgkin lymphoma (NHL). The patients´ 
characteristics are shown in Table 1.  
2.2 Cells and cell cultures 
HMC-1.1 and HMC-1.2 cell lines(37) were kindly provided by Dr. Joseph H. Butterfield ( Mayo 
Clinic, Rochester, MN, USA) and cultured in Iscove's modified Dulbecco's medium (IMDM, 
Gibco-ThermoFisher, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS, 
Sigma, St. Louis, MO, USA), penicillin (100 IU/ml), streptomycin (100 µg/ml) (Biological 
Industries, Beit Haemek, Israel), and α-Thioglycerol (1.2 mM, Sigma). Both HMC-1 cell lines 
were passaged every 3-4 days. LAD2 cells(31) were kindly provided by Drs. A. Kirshenbaum and 
D. Metcalfe (NIH, Bethesda, MD, USA) and were grown in Stem-Pro medium containing Stem-
Pro supplement (Gibco-ThermoFisher), L-glutamine (2 mM), penicillin (100 IU/ml), streptomycin 
(100 μg/ml)  (Biological Industries) and human stem cell factor (SCF,100 ng/ml, a generous gift 
from Swedish Orphan Biovitrum (Sobi)  (Stockholm, Sweden). Half of the cell culture medium 











ROSAKIT WT and ROSAKIT D816V cells were cultured in IMDM in the presence of SCF-containing 
supernatants (10%) of Chinese hamster ovary cells transfected with murine scf and 10% heat-
inactivated FCS. The human lymphoblastoid B cell line RPMI-8866 (ATCC, Rockville, MD, 
USA) and transfectants  were cultured in RPMI-1640 (Gibco-ThermoFisher) supplemented with 
10% FBS, L-glutamine (2 mM), penicillin (100 IU/ml) + streptomycin (100 μg/ml) (Biological 
Industries). RPMI-8866 transfectants were generated using lentiviral transduction and sorted 
according to their GFP reporter expression to obtain uniform expression, like outlined in the 
supplemental methods section. All cell lines were cultured at 37ºC in 5% CO2 and periodically 
checked for Siglec-7 membrane expression by flow cytometry (FC).  
2.3 Cell viability 
HMC-1.1 cells (7× 103/100μl) or LAD2 cells (20× 103/100µl) in their respective culture medium, 
were seeded in flat bottom 96 well cell culture plates (Thermo Scientific Nunc, Israel) with Anti-
Siglec-7 mAb (clone QA79, 10µg/ml, azide-free) or with an isotype-matched control IgG1 (mouse 
IgG1 K Isotype Control Purified, 10 µg/ml, azide-free) both purchased from eBioscience 
(ThermoFisher). The concentration of 10 µg/ml for Anti-Siglec-7 was found to be optimal 
following a dose-response calibration curve. The mAbs were added on the first day of the 
experiment and no additional medium or mAbs were added during the culture time up to 4 days. 
Trypan blue (Sigma) exclusion test was used to determine numbers of viable cells at 24, 48, 72 
and 96 hours (h) of culture.  
Cell viability of HMC-1.1, HMC-1.2 cells (1×104/100μl), LAD2 cells (3×104/100μl) and Siglec-7 
transduced RPMI 8866 cell lines (3×10 3/100μl,see below) was also determined by MTT assay 
(Sigma) ,according to manufacturer’s instructions ,after culturing the cells with Anti-Siglec-7 mAb 











.2.4 FC  
Analysis of Siglec-7 surface expression on primary mast cells (MC) and MCs lines (ROSA KIT WT 
cells and ROSAKIT 816V) was performed after incubation with Fc-blocking reagent and staining 
with monoclonal antibodies (mAb) including PE-labeled anti-Siglec-7 mAb clone QA79 
(eBiosciences) or clone 6-434 (Biolegend). Bone marrow (BM) MC were obtained from SM 
patients (ISM, ASM, SM-AHN and MCL) or patients with lymphoproliferative neoplasms. 
Expression of Siglec-7 was analyzed by FC on a FACS Canto (BD Biosciences). A detailed 
description of FC is provided in the Supplement. 
2.5 Generation of Siglec-7 and RPMI-8866 mutant subclones by transfection 
The inserts for the expression vectors encoding full-length Siglec-7, or mutants lacking both ITIM-
like and ITIM generated by PCR, cloning and transfection procedures in 8866 cells are described 
in the Supplement. 
2.6 Mouse mastocytosis xenograft model 
SCID-beige mice (males, 6-7 weeks old, Harlan, ENVIGO, UK) were maintained in SPF 
conditions. Mice were shaved in the flank and injected subcutaneously (sc) with HMC-1.1 or 
HMC-1.2 or with Siglec-7 transduced RPMI 8866 cell lines (0.5×106 /100µl ice cold PBS). 
 In the “preventive” protocol, mice (6-7/group) were injected intraperitoneally (i.p) with either 
anti-Siglec-7 or IgG1 (4 µg/kg in 100µl ice cold PBS), 30 minutes (min) after either HMC-1.1, 
HMC-1.2 or Siglec-7 transduced RPMI 8866 tumor cell inoculation and every other day until 
tumors reached ~1.5 cm by caliper measurement (according to Hebrew University ethical animal 
guidelines). Mice were consequently euthanized (Figure 4A). In the "treatment" protocol, mice 
(10/ group) were injected ip with either Anti-Siglec-7 or IgG1 (8µg/ kg in 100µl ice cold PBS) 











every other day until tumors reached ~1.5 cm. At that time, mice were euthanized (Figure4D). 
Mice of all the experiments were checked every other day for tumor growth using the caliper and 
for changes in weight or signs of sickness. Upon euthanasia, tumors were excised, weighted and 
divided into different sections for further immunohistochemical (4% paraformaldehyde) and 
Western Blot analyses. 
2.7 Histochemistry & Immunohistochemistry 
Histochemistry and immunohistochemistry were performed on paraffin-embedded tissue samples 
as described in the Supplement. 
2.8 Western Blot  
Western Blot analysis was performed according to standard procedures on lysates from HMC-1.1 
cells and from excised tumors (13). Membranes were probed with the following antibodies: anti-
phospho-SHP-1 and anti-SHP-1 (each 1:200, Santa Cruz Technology, Santa Cruz, CA, USA), anti-
phospho-Bcl2 (Ser 70), Bcl2, anti-phospho-KIT and anti-KIT (each 1:1000, Cell Signaling 
Technology), anti-Vinculin and anti-GAPDH (1:1000, Santa Cruz Technology). Signal was 
acquired using BioRad Chemi Doc XRS + Gel imaging system and bands quantified using Image 
Lab software. 
2.9 Statistical analysis 
Data are expressed as the mean ± standard deviation (SD). Unpaired two-tailed Student’s t-test 











3. Results   
3.1 Siglec-7 is expressed on MCs obtained from mastocytosis patients and on ROSA cell lines 
In this study, by FC analysis, we have established that CD34-/CD45+/CD117+ BM MCs (dead cell 
exclusion test was not used; for gating strategy see Supplementary Figure 1)) obtained from 
patients with ISM (n=5), ASM (n=2), SM-AHN (n=2), or MCL (n=1) all stained positive for 
surface Siglec-7 with two different mAbs (QA and 6434), independently of the variant of SM 
(shown as dot plots in Figure 1 and histograms in Supplementary Figure 2  and Table 1). 
Interestingly, Siglec-7 was also found to be expressed on MCs in BM samples obtained from 
patients with lymphoproliferative neoplasms, without major differences in staining intensities 
when comparing MCs in control BM and BM MCs of mastocytosis patients (Supplementary 
Figure 3). Moreover, we have found that that both ROSA KIT WT cells and ROSAKIT 816V cell lines 
express Siglec-7 (Supplementary Figure 4) as previously shown for  normal human MCs and the 
MCL cell lines HMC-1.1, HMC-1.2 and LAD2 (10). 
 
New Figure 1:  
 











Bone marrow (BM) cells were obtained from patients with indolent systemic mastocytosis (ISM, 
n=5) or advanced SM, including aggressive SM (ASM; n=2), SM with an associated hematologic 
neoplasm (AHN, n=2) or MC leukemia (MCL, n=1). Patients with AHN were suffering from ASM 
with an associated myelodysplastic/myeloproliferative overlap neoplasm (ASM-MDS/MPN; n=1) 
or from ASM with associate acute myeloid leukemia (ASM-AML; n=1). BM cells were stained 
with two monoclonal antibodies against Siglec-7, QA79 (left plot) or 6-434 (right plot) by 
multicolor FC as described in the text. Surface expression of Siglec-7 on CD34-/CD45+/CD117+ 
MC was determined as median fluorescence intensity (MFI) and expressed as staining-index (SI) 


















Old table 1: 
Table 1- Patients´ characteristics and expression levels of Siglec-7 on primary neoplastic mast 
cells (MCs) and MCs in control bone marrow (BM) samples. 
Staining index (SI) for Siglec-7 (clones: QA79 and 6-434) obtained with MCs from patients with non-
advanced and advanced SM and in control BM samples. Bone marrow (BM) cells were obtained from 
patients with indolent systemic mastocytosis (ISM, n=5) or advanced SM, including aggressive SM 
(ASM; n=2), SM with an associated hematologic neoplasm (AHN, n=2) or MC leukemia (MCL, n=1). 
Patients with AHN were suffering from ASM with an associated myelodysplastic/myeloproliferative 
overlap neoplasm (ASM-MDS/MPN; n=1) or from ASM with associate acute myeloid leukemia (ASM-
AML; n=1). Expression of Siglec-7 on BM MCs was determined by multi-color flow cytometry (FC) 
using isotype-matched control antibodies and two monoclonal antibodies (mAb) against Siglec-7, 











Surface expression of Siglec-7 on CD34-/CD45+/CD117+ MCs was determined as median fluorescence 
intensity (MFI) and expressed as staining-index (SI) according to the formula: SI = MFI (test mAb) / 
MFI (isotype-control Ab). Results were scored as follows: SI 0-1.3, –; SI 1.31-3, ±; SI 3.01-10, +; SI 
>10, ++. *BM infiltration with neoplastic MCs was determined by immunohistochemistry using an 
antibody against tryptase. WHO, World Health Organization. 
 
 
3.2 Siglec-7 activation on MCL cell lines down-regulates their viability 
In the present work, we asked whether Siglec-7 activation by specific mAbs will inhibit 
transformed MCs growth. To test this hypothesis, we incubated HMC-1.1, HMC-1.2 and LAD2 
cells with Anti-Siglec-7 mAb or the isotype control (IgG1). Anti-Siglec-7 (10µg/ml, optimal 
concentration), significantly decreased the viability (MTT assay) of all the 3 cell lines at 72 h of 
culture to 66 ± 11% ,71± 6% and 87± 3 % viable cells (mean ±SD,***p<.0005),(Figure 2A) , for 
HMC-1.1, HMC-1.2 and LAD2 respectively). Moreover, the numbers of viable HMC-1.1 (Figure 
2B) and LAD2 cells (Supplementary Figure 5A) as determined by Trypan Blue staining, were 
significantly reduced in cultures containing Anti-Siglec-7 in a time-dependent fashion. At 24, 48 
and 72 h, viable HMC-1.1 in Anti-Siglec-7 treated cultures were respectively 7036± 1373, 10150 
± 1616 and 15500 ± 2166 cells/ml, mean ±SD, and in IgG1 treated cultures were respectively 
10281 ± 1218cells/ml ( p*** <.0005), 13869 ± 2192 (* p<.05 ) and 25226± 3190 mean ±SD ( *** 
p<.0005) (Figure 2B). In LAD2, the decrease in viable cells in Anti-Siglec-7 cultures was 
significantly different from the ones in IgG1 only at 72h (33260 ± 2789 vs 42625 ± 2473 cells/ml, 
*p=0.0458) (Supplementary Figure 5A). 
Therefore, it seems that Anti-Siglec-7 mediated inhibition of survival is more pronounced in 
HMC-1 cells than in LAD2 cells. Nevertheless, no signs of apoptosis as assessed by cleaved 











Siglec-7 mAb (not shown). Cell numbers in Anti-Siglec-7 treated HMC-1.1 and LAD2 were 
significantly reduced, as expected, also following Midostaurin (1 µM) incubation at all three time 
points assessed. Importantly, cell surface expression of Siglec-7 was stable on HMC-1.1 and 
LAD2 cells even after a 72h treatment with Anti-Siglec-7 (Figure 2C and Supplementary Figure 
5B).  
 
Figure 2- Siglec-7 activation down-regulates survival of mast cell leukemia (MCL) cell lines.  
(A) Cell viability of HMC-1.1, HMC-1.2 and LAD2 cells treated with Anti-Siglec-7 mAb (10 
µg/ml) or control IgG1 (10 µg/ml) for 72 hours (h) by MTT assay. Data are expressed as mean ± 
SD (%) of viable cells, calculated by dividing numbers of Anti-Siglec-7-treated cells by numbers 
of IgG1 treated cells multiplied by 100. n=3, Anti-Siglec-7 vs IgG1, ***: p<.0005.  
(B) Numbers of Trypan blue negative HMC-1.1 cells (cells/ml) treated with Anti-Siglec-7 or IgG1 
for different time points. Data are expressed as mean ± SD. n=5. Anti-Siglec-7 vs IgG1, *, p<.05 











HMC-1.1 cells after treatment (24, 48, or 72 h) with Anti-Siglec-7 mAb or IgG1. Afterwards cells 
were incubated with strip buffer in order to eliminate bound Ab and stained with Anti-Siglec-7 
and goat anti-mouse Ab (647GαM Ab) or with 647GαM Ab alone. The histograms are 
representative of 3 independent experiments. 
 
3.3 Siglec-7 activation on HMC-1.1 cells causes recruitment of SHP-1 and de-phosphorylation 
of KIT and its downstream signaling pathway molecules 
Next, we tested whether SHP-1 is phosphorylated following activation of Siglec-7 on HMC-1.1 
cells. As can be seen in Figure 3A, SHP-1 is phosphorylated as early as 2 min after incubation 
with Anti-Siglec-7 (295.56% ± 123.06, *p=0.0409). SHP-1 has been found to interact with KIT 
by binding selectively to the phosphorylated KIT juxtamembrane region and to negatively regulate 
KIT-mediated cell proliferation (39). We therefore hypothesized that Siglec-7 might exert its 
effects at least in part via de-phosphorylation of KIT and possibly also by inhibition of RAS/RAF 
and JAK/STAT signaling pathways. HMC-1.1 cells incubated with Anti-Siglec-7 displayed a 
reduction, even if not significant, in KIT phosphorylation after 30 min (17.48% ±13.25, Western 
Blot) (Figure 3B) as well as in KIT downstream signaling molecules, i.e.  SYK, STAT6, ERK and 











Figure 3- Siglec-7 activation on HMC-1.1 cells causes recruitment of SHP-1 and de-
phosphorylation of KIT. 
HMC-1.1 cells were incubated in medium, or with Anti-Siglec-7 mAb or with IgG1 for different 
time periods as indicated. (A) Phosphorylation of SHP-1 at 2 min as assessed by Western Blot 
analysis using Abs against phosphorylated SHP-1 (pSHP-1) and total SHP-1 and GAPDH as a 
loading control and quantified by densitometry. The blot is a representative of 5 independent 
experiments. Western Blot densitometry values were obtained by dividing the intensity of each 
band by the loading control and then by the total SHP-1 protein. Data are expressed as mean ± SD, 











 (B) Phosphorylation of KIT at 30 min  as assessed by Western Blot analysis using Abs against 
phosphorylated KIT (pKIT) and total KIT  and GAPDH as a loading control and quantified by 
densitometry. Western Blot densitometry graphs were obtained as described in A. The blot is a 
representative of 3 independent experiments.   
 
3.4 Anti-Siglec-7 inhibits the development of HMC-1.1 tumor growth in SCID-beige mice by 
apoptosis and by cell cycle arrest  
Finally, we aimed to test the effect of Anti-Siglec-7 in vivo in MCL xenograft models. For this, we 
injected HMC-1.1 or HMC-1.2 cells (0.5×106) sc into SCID-beige mice (40) followed by Anti-
Siglec-7 or IgG1 ip treatment. We initially employed the “preventive” protocol in which mice were 
injected with Anti-Siglec-7 mAb or with an IgG1 (4µg/kg), 30 min after tumor cell injection (day 
1) and thereafter, every other day until tumor size reached ~1.5 cm (Figure 4A). At this point (day 
50), mice were euthanized, and tumors were excised. In both HMC-1.1 and HMC-1.2 bearing mice 
injected with Anti-Siglec-7, tumor weight was significantly reduced as compared with mice 
injected with the control Ab. In HMC-1.1 grafted mice, values for anti-Siglec-7 treated mice were 
173 ± 55 mg, mean ± SD and for IgG1 treated mice 398 ± 84 mean± SD (n=12 mice from 2 
different pooled experiments *p< 0.05 Figure 4B). In HMC-1.2 grafted mice, values were 33260 
± 2789 mean ± SD for anti-Siglec-7 treated mice and 42625 ± 2473 mean ± SD for IgG1 treated 
mice (n=14 mice from 2 different pooled experiments, p*=0.0378 (Supplementary Figure 6).  
Immunohistochemical staining of the Anti-Siglec-7 treated HMC-1.1 tumors with anti-cleaved 
Caspase-3 (Figure 4C upper panel), anti-phosphohistone-3 (Figure 4C middle panel) and anti-
phospho-KIT (Supplementary Figure 7) revealed a significant increase in the number of apoptotic 











panel), decrease in mitosis (6 ± 2 mean ± SD for anti-Siglec-7 treated mice slides and 9 ± 4 mean 
± SD for IgG1 treated mice slides *p< 0.05 (Figure 4C middle panel) and KIT de-phosphorylation 
(0.008 ± 0.010 mean ± SD for anti-Siglec-7 treated mice slides and 0.016 ± 0.017 mean ± SD for 
IgG1 treated mice slides ***p< 0.0005 (Supplementary Figure 7) indicating induction of 
apoptosis, and cell cycle inhibition in vivo. In line with these observations, MCs numbers, 
evaluated by Toluidine blue staining, were markedly reduced upon Anti-Siglec-7 treatment (49.56 
±20.23 mean ± SD for anti-Siglec-7 treated mice slides and 83.69 ± 29.05 mean ± SD for IgG1 
treated mice slides *p< 0.05 (Figure 4C lower panel). 
In a next step, we tested if the injection of Anti-Siglec-7 would be effective against established 
tumors. Following a different protocol, the first injection of Anti-Siglec-7 or of IgG1 (8µg/kg) was 
performed when HMC-1.1 engrafted SCID-beige mice displayed palpable tumors, i.e. day 20; and 
thereafter injections were performed every other day until the tumor size reached ~1.5 cm (Figure 
4D). Remarkably, treatment with Anti-Siglec-7 significantly inhibited and sometimes even 
abolished the growth of the established HMC-1.1 tumors as evidenced a substantial reduction of 
tumor weight in Anti-Siglec-7 treated mice compared to that measured in IgG1 control -treated 
mice (26. ±4 mean ± SD for anti-Siglec-7 treated mice and 173 ± 32 mean ± SD for IgG1 treated 
mice (n=18 mice from 2 different pooled experiments p***<.0005) (Figure 4E). Moreover, in this 
model a pronounced de-phosphorylation of the anti-apoptotic molecule Bcl-2 was found in tumor 





















Figure 4- Anti-Siglec-7 inhibits the development of HMC-1.1 tumor growth in SCID/beige 
mice by apoptosis and by cell cycle arrest. 
(A) Schematic representation of the treatment schedule of HMC-1.1 cells grafted mice. Anti-
Siglec-7 injection started immediately after cell inoculation. HMC-1.1 cells (0.5×106 /100 µl) were 
injected subcutaneously (sc) into SCID-beige mice at day 0. Intraperitoneal injections (ip) of Anti-
Siglec-7 or IgG1 (each 4 µg/kg) were performed at 30 min, 24 h later and then every other day 
until tumors reached 1.5 cm and mice were euthanized. (B) Tumor weight (mg) of Anti-Siglec-7 
or IgG1 treated mice as described in (A), Results represent the mean ± SD of 2 independent 
experiments. (n=12 mice from 2 different pooled experiments) * p < .05 (C) 
Immunohistochemistry of tumor sections from mice treated with Anti-Siglec-7 or IgG1 stained 
with anti-cleaved Caspase-3 or anti-Phospho-Histone-3 or Toluidine Blue and densitometric 
quantification (positive cells, # per field).  Left panels are photomicrographs of a representative 
experiment. Densitometry analyses (right panels) represent the mean ± SD of 2 independent 
experiments for anti-cleaved Caspase-3, anti-Phospho-Histone 3 and for Toluidine blue staining. 
Red arrows indicate mast cells (MCs), Scale bars=100 µm. *p< 0.05 (D) HMC-1.1 cells (0.5×106 
/100 µl) were injected sc into SCID-beige mice at day 0. Anti-Siglec-7 or IgG1 (each 8 µg/kg) 
were injected ip at day 20 when the tumor became palpable, and then injected every other day until 
tumors reached 1.5 cm and mice were euthanized. (E) Tumor weight (mg) of Anti-Siglec-7 or 
IgG1 treated mice. Results represent the mean ± SD of 2 independent experiments. (n=18 mice 
from 2 different pooled experiments) p***<.0005 (F) Western Blot analysis for Bcl-2 
phosphorylation of tumor tissue lysates from mice treated with Anti-Siglec-7 or IgG1. The blot 












3.5 Siglec-7 cytoplasmic domain contributes to Anti-Siglec-7 mediated anti-survival effects in 
vitro and in vivo. 
The cytoplasmic domain of Siglec-7 contains two signaling motifs: a membrane-proximal ITIM, 
and a membrane-distal ITIM-like motif, both of which were shown to be involved in the 
recruitment of SHP-1 upon activation in NK cells(41). To investigate whether these motifs are 
essential for the Anti-Siglec-7 activity toward neoplastic target cells, we transduced the Siglec-7-
negative human lymphoblastoid B cell line RPMI-8866 cells with empty vector containing GFP 
only (GFP+, used as control), full length Siglec-7 (CDS) and truncated Siglec-7 (Truncated) 
lacking the entire cytoplasmic tail. When the Siglec-7 expressing CDS cells were exposed to Anti-
Siglec-7, a significant reduced cell viability was detected (MTT assay, 75 ± 8 mean ± SD for anti-
Siglec-7 treated CDS; 86± 7 mean ± SD for anti-Siglec-7 treated Truncated cells at 72h; and 77 ± 
10 mean ± SD for anti-Siglec-7 treated CDS and 87±4 mean ± SD for anti-Siglec-7 treated 
Truncated cells at 96h Figure 5A) although, cells expressing truncated Siglec-7 were also inhibited 
even if at a lesser degree (Figure 5A). This indicates that in vitro the Siglec-7 tail takes part in its 
inhibitory effects, possibly together with other elements of the Siglec-7 receptor.  
To further confirm the importance of the cytoplasmic domain of Siglec-7, we injected (sc) GFP+  
or CDS or Truncated 8866 cells (0.5×106 ) into SCID-beige mice(40) followed by Anti-Siglec-7 
(ip) as described above for HMC-1.1 (Figure 4A). We found, in line with our in vitro results, that 
treatment with Anti-Siglec-7 significantly reduced tumor growth in mice grafted with cells 
displaying full-length Siglec-7 (CDS). In fact, the tumor weight in these mice was significantly 
lower compared to the tumor weight in mice injected with cells expressing truncated Siglec-7 or 











379 ± 71 mg mean ± SD for truncated tumor grafted mice and 416 ± 89 mg mean ± SD for GFP+ 












Old figure 5: 
 
NewFigure 5: 
Figure 5- Siglec-7 cytoplasmic domain contributes to Anti-Siglec-7 mediated anti-survival 











RPMI 8866 (8866) cells transfected either with GFP (GFP+, used as control), or with Siglec-7 
extracellular domain without the cytoplasmic tail (Truncated) or with the intact Siglec-7 (CDS) 
were treated with Anti-Siglec-7 (10 µg/ml) or IgG1 (10 µg/ml) for different time points. (A) Cell 
viability (MTT assay). Data are shown as % of viable cells and expressed as mean ± SD of 5 
independent experiments. *p <0.05. CDS vs. Truncated at 72 h and 96 h. (B) 8866 cells GFP+, 
Truncated or CDS (0.5x106 /100 µl) were injected subcutaneously (sc) into SCID-beige mice at 
day 0. Anti-Siglec-7 or IgG1 ip injections (4 µg/kg) were performed like described in 3A. Tumor 
weight (mg) of Anti-Siglec-7 treated GFP+ or Truncated or CDS tumors grafted mice. Results 
represent the mean ± SD of 2 independent experiments. (n=18 mice from 2 different pooled 
experiments) *p< 0.05. 
 
4. Discussion 
Treatment of advanced mastocytosis has substantially improved by the development of more 
selective and more potent tyrosine kinase inhibitors (17-19, 33) and ongoing efforts are now 
involving KIT D816V inhibitors (42). However, the disease is still incurable and most of the 
patients relapse or have resistant disease. Therefore, it is of crucial importance to identify novel 
therapeutic targets and to develop new improved anti-neoplastic therapies for these patients.  
Previous reports have described some growth inhibition by activating either Siglec-2(43), Siglec-
3(44), or to a much lesser degree Siglec-7(45) in AML cells and malignant B lymphocytes. 
Here we investigated whether Siglec-7 can be harnessed to inhibit the growth of neoplastic MCs. 
We first examined Siglec-7 expression on primary MCs obtained from patients with mastocytosis 
and in several human MCL lines. As assessed by FC, MCs obtained from patients with ISM, 











However, we observed variations in Siglec-7 expression levels between the SM patients that might 
be due to the fact that dead cell exclusion test was not applied. Furthermore, Siglec-7 was found 
to be expressed on MCs in control BM samples. These data suggest that Siglec-7 expression on 
MCs is neither dependent on oncogenic signaling networks nor on specific mutations in KIT. In 
addition, we were able to show that Siglec-7 is expressed on ROSA WT KIT cells and ROSA KIT 816V 
cells as we previously described for HMC-1.1 cells, HMC-1.2 harboring KIT D816V, and LAD2 
cells (10). 
Because of the limited availability of mastocytosis patients and the restricted MCs numbers that 
can be recovered from the patients´ BM, we assessed Anti-Siglec-7 mediated effects in the MCL 
lines HMC-1.1(30) and LAD2(31). Anti-Siglec-7 reduced cell viability in a time-dependent 
fashion although no clear signs of apoptosis were displayed. This result was somehow expected. 
In fact, normal cells such as human cord blood derived MCs (10) and human peripheral blood 
eosinophils (13) incubated with Anti-Siglec-7, did not undergo cell death but rather inhibition of 
mediator release. It has also been shown that Anti-Siglec-7 on human monocytes mediates 
cytokine-production probably related to the presence of an activating form of Siglec-7 (46). 
Apoptotic mechanisms were, on the other hand, shown by incubation of platelets with the Siglec-
7 natural ligand ganglioside GD2(47), suggesting that activation of Siglec-7 can sometimes also 
modulate survival-mediating processes, at least in platelets. 
As other IR ,Siglec-7 activation  at least on NK cells, MCs and eosinophils  has been demonstrated 
to lead to SHP-1 recruitment (13,38,48). Therefore we tested whether SHP-1 is phosphorylated 
following activation of Siglec-7 on HMC-1.1 and detected that it is significantly increased. SHP-
1 is a known negative regulator of KIT (49-51). Siglec-7 activation of HMC-1.1 cells was found 











significant fashion. These data show that the inhibitory cascade activated by Anti-Siglec-7 is 
mediated by SHP-1 and might impact directly or indirectly KIT downstream signaling pathways. 
Interestingly, we have previously demonstrated that in HMC-1.1 cells an anti-CD300a/anti-KIT 
bispecific antibody designed to activate the CD300a IR, caused SHIP-1 phosphorylation but not 
SHP-1, SYK and LAT de-phosphorylation but not KIT de-phosphorylation (52). The different 
results obtained by activating CD300a or Siglec-7 on HMC-1.1 might be due to the differences in 
the recruited phosphatase and adaptor molecules and demonstrate that SHP-1 is well-linked to KIT 
de-phosphorylation. 
Using immuno-deficient SCID-beige mice that lack NK cells, grafted with HMC-1.1 cells, we 
found that Anti-Siglec-7 inhibits the growth of these tumors both when the mAb is administered 
immediately after the cell injection, and when the tumor is already established. These strong in 
vivo results, in comparison to the weaker in vitro ones, are nevertheless in line with them. Indeed, 
in vivo the inhibitory effects seem to be the result of anti-Siglec-7 induced KIT de-phosphorylation 
together with induction of apoptosis and cell cycle arrest, as shown by cleaved Caspase-3, de-
phosphorylation of Bcl-2, and reduction of phospho-histone 3, that in concert result in reduced 
MCs numbers in the Anti-Siglec-7 treated tumors.  
The strength of the in vivo data, in comparison to the in vitro ones, might be the result of a number 
of tumor microenvironment factors such as hypoxia, the expression of Siglec-7 ligand in the 
matrix, etc., rendering the tumor cells more sensitive to Anti-Siglec-7. Therefore, the lack of Anti-
Siglec-7 effect on cell proliferation or cell death on primary patient-derived MCs (not shown) 
might be due to the “simplified” in vitro environment and /or to the specific patient and disease 
together with the specific drug treatment. Therefore, other tests with human primary mastocytosis 











To investigate whether the whole Siglec-7 receptor and consequent signal transduction are needed 
for the inhibitory effects, we transduced RPMI-8866 cells with empty vector containing GFP, full-
length Siglec-7, and truncated Siglec-7 lacking the entire cytoplasmic tail. We observed in vitro 
that Anti-Siglec-7 strongly inhibited RPMI-8866 cells carrying full-length Siglec-7, but also 
moderately inhibited cells carrying only the extracellular portion of Siglec-7. Interestingly, 
clustering of Siglec-7 with a specific F(ab′)2 on the monocytic cell line U937 carrying Siglec-7 
lacking the cytosolic ITIM domain, induced non-apoptotic cell death probably via ROS production 
by an unclear mechanism(53). Nevertheless, only the full length Siglec-7 cells had a significantly 
reduced tumor weight when treated with Anti-Siglec-7 in vivo. 
Other members of the Siglec family, such as Sialoadhesin, Siglec-H or Siglec-14 have also been 
reported to function even when lacking the tyrosine-based signaling motif (7). Moreover, some 
ITIM bearing receptors have been described to act sometimes as positive regulators of cell 
functions and vice versa (54) complicating the whole scenario.  
In conclusion, we have shown that primary neoplastic MCs from BM of mastocytosis patients, as 
human MC lines, express Siglec-7. Moreover, we demonstrated that activation of Siglec-7 inhibits 
the in vitro growth and viability of human MC lines and their in vivo growth in immune 
compromised mice. Finally, our data suggest that Siglec-7 mediates growth inhibition in 
transformed MCs by activating phosphorylation of SHP-1 and de-phosphorylation of KIT and of 
other signal transduction molecules. We therefore hypothesize that Anti-Siglec-7 mAb application 
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